PDL BioPharma Financial Indicators Patterns

PDLI -- USA Stock  

USD 3.19  0.03  0.95%

Please use analysis of PDL BioPharma fundamentals to determine if markets are correctly pricing the firm. We found thirty-seven available financial ratios for PDL BioPharma which can be compared to its competitors. To make sure the equity is not overpriced, please check all PDL BioPharma fundamentals including its Price to Book, Total Debt, Number of Employees, as well as the relationship between EBITDA and Cash Flow from Operations . Given that PDL BioPharma has Price to Earning of 3.38X, we recommend you check out PDL BioPharma recent market performance to make sure the company can sustain itself for few more years. Use PDL BioPharma to enhance returns of your portfolios. The stock experiences moderate upward volatility. Check odds of PDL BioPharma to be traded at $3.51 in 30 days.
Enterprise Value

PDL BioPharma Company Summary

PDL BioPharma competes with China Cord, Equillium, NantKwest, DelMar Pharmaceuticals, and Denali Therapeutics. PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada. PDL BioPharma operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 104 people.

PDL BioPharma Retained Earnings vs Revenue

PDL BioPharma is considered to be number one stock in retained earnings category among related companies. It is regarded second in revenue category among related companies totaling about  0.15  of Revenue per Retained Earnings. The ratio of Retained Earnings to Revenue for PDL BioPharma is roughly  6.65 

PDL BioPharma Systematic Risk

The output start index for this execution was fifteen with a total number of output elements of twenty-four. The Beta measures systematic risk based on how returns on PDL BioPharma correlated with the market. If Beta is less than 0 PDL BioPharma generally moves in the opposite direction as compared to the market. If PDL BioPharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one PDL BioPharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of PDL BioPharma is generally in the same direction as the market. If Beta > 1 PDL BioPharma moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

Distress Rating

PDL BioPharma Financial Distress Probability

38%
Chance of Financial Distress
PDL BioPharma has less than 38 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info

Compare PDL BioPharma

Compare PDL BioPharma To Peers

PDL BioPharma Opportunity Range

January 16, 2019 Opportunity Range

Additionally take a look at Your Equity Center. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Search macroaxis.com